Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma
Conditions
Interventions
BA3182
Locations
9
United States
UC Irvine
Irvine, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Northwestern University
Chicago, Illinois, United States
University of Illinois
Chicago, Illinois, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Start Date
July 14, 2023
Primary Completion Date
September 15, 2028
Completion Date
September 15, 2028
Last Updated
September 25, 2025
NCT05101356
NCT01506973
NCT04739722
Lead Sponsor
BioAtla, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions